Research shows that high-titer (antibody-rich) COVID convalescent plasma -- when administered to COVID-19 outpatients within nine days after testing positive -- reduced the need for hospitalization ...

Johns Hopkins Medicine researchers report that a prospective study of 14 infants and children demonstrated that convalescent plasma—a blood product collected from patients recovered from infections ...

Findings from a nationwide, multicenter study led by Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health suggest that patients with COVID-19 have less chance of developing ...

A new study led by researchers at Johns Hopkins Bloomberg School of Public Health estimates that thousands of lives could have been saved during the first year of the COVID-19 pandemic if convalescent ...

Three years into the COVID-19 pandemic, new variant outbreaks continue to fuel economic disruptions and hospitalizations across the globe. Effective therapies remain unavailable in much of the world, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Fewer patients with COVID-19-induced ARDS who received ...

In a study published in the New England Journal of Medicine, clinicians and researchers from the CHU of Liège and the University of Liège show that the administration of plasma taken from convalescent ...

Two ongoing trials may provide additional clarity regarding the use of convalescent plasma in patients with Covid-19. The COVIC-19 trial (Early High-Titre Convalescent Plasma in Clinically Vulnerable ...

The New England Journal of Medicine (NEJM) today published final results of a nationwide multicenter study led by researchers at Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public ...

Findings from a nationwide, multicenter study led by Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health suggest that patients with COVID-19 have less chance of developing ...